{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
adenosine
to a specific field?
Status:
Investigational
Class:
NUCLEIC ACID
Status:
Investigational
Source:
Ann Oncol. Mar 2008;19(3):520-6.: Phase 3 Human clinical trial Completed Stomach Neoplasms/mortality/surgery
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
INN:pozetaldogene ormesparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:rivunatpagene miziparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:simoladagene autotemcel [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
First approved in 2004
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04686175: Phase 1/Phase 2 Interventional Recruiting Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
(2021)
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
NCT02754141: Phase 1/Phase 2 Interventional Completed Malignant Solid Tumor
(2016)
Source URL:
Class:
CONCEPT
Status:
US Approved Rx
(2008)
Source:
NDA022161
(2008)
Source URL:
First approved in 2008
Source:
NDA022161
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Regadenoson (Lexiscan), a low affinity agonist of the A2A adenosine receptor, increases coronary blood flow (CBF) and mimics the increase in CBF caused by exercise. Myocardial uptake of the radiopharmaceutical is proportional to CBF creating the contrast required to identify stenotic coronary arteries. It is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. The most common adverse reactions to Lexiscan are dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, and nausea. Methylxanthines, e.g., caffeine and theophylline, may interfere with the activity of Lexiscan. Aminophylline may be used to attenuate severe and/or persistent adverse reactions to Lexiscan.
